{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.999","value":"77.31"},{"groupId":"OG001","spread":"1.080","value":"75.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"293"},{"groupId":"OG001","value":"287"}],"units":"Participants"}],"title":"Cycle 1 (Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.188","value":"74.39"},{"groupId":"OG001","spread":"1.080","value":"76.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"268"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.093","value":"74.20"},{"groupId":"OG001","spread":"1.122","value":"76.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.118","value":"74.14"},{"groupId":"OG001","spread":"1.115","value":"77.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.220","value":"73.30"},{"groupId":"OG001","spread":"1.212","value":"77.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"233"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.250","value":"73.51"},{"groupId":"OG001","spread":"1.130","value":"78.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"title":"Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.267","value":"72.27"},{"groupId":"OG001","spread":"1.180","value":"77.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.226","value":"73.96"},{"groupId":"OG001","spread":"1.213","value":"77.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"title":"Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.424","value":"72.93"},{"groupId":"OG001","spread":"1.168","value":"79.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.139","value":"71.79"},{"groupId":"OG001","spread":"1.283","value":"76.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"306"}],"units":"Participants"}],"description":"Patient-reported outcomes (PROs) assessed health-related quality of life (QoL) by the EuroQoL Group health status questionnaire (EQ-5D), which was a brief self-administered, validated instrument with 2 parts. The first part assessed the current health state. In this outcome measure, the second part was applied to assess the general health status by using visual analog scale (EQ-5D VAS) which measured participant's self-rated health status on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).","dispersionType":"Standard Error","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or a different drug from that to which they were randomized. Here, 'Number analyzed' signifies the number of participants evaluable at specified time-points.","reportingStatus":"POSTED","timeFrame":"Cycle 1(Day 1); subsequent cycles (Day 1) and end of treatment/withdrawal (ie, up to 1 year)","title":"PROs- EuroQol European Quality of Life Questionnaire Variable Analogue Scale (EQ-VAS) Observed Means","type":"SECONDARY","unitOfMeasure":"Units on a scale"}